Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Profit After Tax (2023 - 2025)

Zenas BioPharma has reported Profit After Tax over the past 3 years, most recently at -$240.4 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$240.4 million for Q4 2025, down 357.15% from a year ago — trailing twelve months through Dec 2025 was -$377.7 million (down 140.62% YoY), and the annual figure for FY2025 was -$377.7 million, down 140.59%.
  • Profit After Tax for Q4 2025 was -$240.4 million at Zenas BioPharma, down from -$51.5 million in the prior quarter.
  • Over the last five years, Profit After Tax for ZBIO hit a ceiling of $35.6 million in Q3 2023 and a floor of -$240.4 million in Q4 2025.
  • Median Profit After Tax over the past 3 years was -$38.3 million (2024), compared with a mean of -$52.4 million.
  • Peak annual rise in Profit After Tax hit 20.77% in 2025, while the deepest fall reached 357.15% in 2025.
  • Zenas BioPharma's Profit After Tax stood at -$24.6 million in 2023, then crashed by 113.56% to -$52.6 million in 2024, then crashed by 357.15% to -$240.4 million in 2025.
  • The last three reported values for Profit After Tax were -$240.4 million (Q4 2025), -$51.5 million (Q3 2025), and -$52.2 million (Q2 2025) per Business Quant data.